Eupraxia Pharmaceuticals Inc.
NASDAQ: EPRX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- James A. Helliwell
- Employees
- 49
- Headquarters
- Victoria, Canada
- IPO year
- 2024
- Market cap
- $209.3M
- Website
- https://www.eupraxiapharma.com
Loading EPRX…
Loading profile data…Frequently asked questions about EPRX
What does Eupraxia Pharmaceuticals Inc. (EPRX) do?
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Ph...
Where does EPRX trade?
Eupraxia Pharmaceuticals Inc. (EPRX) trades on the NASDAQ.
What sector is EPRX in?
Eupraxia Pharmaceuticals Inc. (EPRX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Eupraxia Pharmaceuticals Inc.?
James A. Helliwell is the chief executive officer of Eupraxia Pharmaceuticals Inc. (EPRX).
Where is Eupraxia Pharmaceuticals Inc. headquartered?
Eupraxia Pharmaceuticals Inc. is headquartered in Canada.
Does EPRX pay a dividend?
Eupraxia Pharmaceuticals Inc. (EPRX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did EPRX go public?
Eupraxia Pharmaceuticals Inc. (EPRX) completed its initial public offering in 2024.